1.            Balash, Y. et al. Is There Horizontal Transmission of Creutzfeldt-Jakob Disease? Neuroepidemiology 57, 156–161 (2023).

2.            Anis, E. et al. Reporting of Allergic Reactions During Pfizer-BioNTech BNTT162B2 Vaccination in Israel. J. Allergy Clin. Immunol. Pract. 10, 2969–2976 (2022).

3.            Mevorach, D. et al. Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel. Circulation 146, 802–804 (2022).

4.            Stein, M. et al. How compassionate use enabled Israel to deliver the Pfizer-BioNTech COVID-19 vaccination to vulnerable children aged 12–15 years before regulatory approval. Acta Paediatr. Int. J. Paediatr. 111, 834–841 (2022).

5.            Mevorach, D. et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N. Engl. J. Med. 386, 998–999 (2022).

6.            Haas, E. J. et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect. Dis. 22, 357–366 (2022).

7.            Green, M. S. et al. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines 10, (2022).

8.            Gorelik, Y., Anis, E. & Edelstein, M. Inequalities in initiation of COVID19 vaccination by age and population group in Israel- December 2020-July 2021. Lancet Reg. Heal. - Eur. 12, (2022).

9.            Mevorach, D. et al. Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel. N. Engl. J. Med. 385, 2140–2149 (2021).

10.          Singer, S. R. et al. Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. EClinicalMedicine 42, (2021).

11.          Anis, E. et al. A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19. J. Infect. 83, 678–685 (2021).

12.          Netanel, C. et al. Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015–2016. Vaccine 39, 7101–7107 (2021).

13.          Perepliotchikov, Y. et al. Inferring numbers of wild poliovirus excretors using quantitative environmental surveillance. Vaccines 9, (2021).

14.          Reicher, S. et al. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur. J. Epidemiol. 36, 727–734 (2021).

15.          Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021).

16.          Gozlan, Y. et al. Lessons from intensified surveillance of viral hepatitis a, Israel, 2017 and 2018. Eurosurveillance 26, (2021).

17.          Langsam, D. et al. Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis. Vaccine 38, 2700–2706 (2020).

18.          Tur-Sinai, A. et al. Vaccination uptake and income inequalities within a mass vaccination campaign. Isr. J. Health Policy Res. 8, (2019).

19.          Bercovich, S. et al. Validation of parental reports of rotavirus vaccination of their children compared to the national immunization registry. Vaccine 37, 2791–2796 (2019).

20.          Salama, M. et al. Outbreak of West Nile Virus disease in Israel (2015): A retrospective analysis of notified cases. Travel Med. Infect. Dis. 28, 41–45 (2019).

21.          Lustig, Y. et al. Epidemiologic and phylogenetic analysis of the 2018 west Nile virus (WNV) outbreak in Israel demonstrates human infection of WNV lineage I. Eurosurveillance 24, (2019).

22.          Ghanem-Zoubi, N., Eljay, S. P., Anis, E. & Paul, M. Reemergence of human brucellosis in Israel. Isr. Med. Assoc. J. 21, 10–12 (2019).

23.          Elran, B. et al. Parents’ perceptions of childhood immunization in Israel: Information and concerns. Vaccine 36, 8062–8068 (2018).

24.          Adamker, G. et al. Prediction of Shigellosis outcomes in Israel using machine learning classifiers. Epidemiol. Infect. 146, 1445–1451 (2018).

25.          Anis, E. et al. Did two booster doses for schoolchildren change the epidemiology of pertussis in Israel? J. Public Health Policy 39, 304–317 (2018).

26.          Rosenberg Danziger, C., Anis, E., Gordon, E.-S., Grotto, I. & Danon, Y. L. Reintroducing OPV in Israel on the journey to global polio eradication – Estimation at a low rate of contraindicated population. Vaccine 36, 3717–3720 (2018).

27.          Ghanem-Zoubi, N., Eljay, S. P., Anis, E. & Paul, M. Association between human brucellosis and adverse pregnancy outcome: a cross-sectional population-based study. Eur. J. Clin. Microbiol. Infect. Dis. 37, 883–888 (2018).

28.          Dadon, Y. et al. Outbreak of human leptospirosis linked to contaminated water bodies in Northern Israel, June to August 2018. Eurosurveillance 23, (2018).

29.          Muhsen, K. et al. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011–2015: a case–control study. Clin. Microbiol. Infect. 24, 53–59 (2018).

30.          Lustig, Y. et al. Spatial distribution of West Nile virus in humans and mosquitoes in Israel, 2000–2014. Int. J. Infect. Dis. 64, 20–26 (2017).

31.          Indenbaum, V. et al. Ongoing mumps outbreak in Israel, January to August 2017. Eurosurveillance 22, (2017).

32.          Gozlan, Y. et al. Ongoing hepatitis a among men who have sex with men (MSM) linked to outbreaks in Europe in Tel Aviv area, Israel, December 2016 – June 2017. Eurosurveillance 22, (2017).

33.          Chemtob, D. et al. A national strategic plan for reducing the burden of sexually transmitted infections in Israel by the year 2025. Isr. J. Health Policy Res. 6, (2017).

34.          Tasher, D., Kopel, E., Anis, E., Grossman, Z. & Somekh, E. Causality assessment of serious neurologic adverse events following the bOPV national vaccination campaign in Israel. Isr. Med. Assoc. J. 18, 590–593 (2016).

35.          Glatman-Freedman, A. et al. Near real-time space-time cluster analysis for detection of enteric disease outbreaks in a community setting. J. Infect. 73, 99–106 (2016).

36.          Tasher, D. et al. How many OPV rounds are required to stop wild polio virus circulation in a developed country? Lessons from the Israeli experience. Vaccine 34, 299–301 (2016).

37.          Brosh-Nissimov, T. et al. Preparing for imported ebola cases in israel, 2014 to 2015. Eurosurveillance 20, (2015).

38.          Muhsen, K. et al. Change in incidence of clinic visits for all-cause and rotavirus gastroenteritis in young children following the introduction of universal rotavirus vaccination in Israel. Eurosurveillance 20, (2015).

39.          Kaliner, E. et al. The Israeli public health response to wild poliovirus importation. Lancet Infect. Dis. 15, 1236–1242 (2015).

40.          Kalkowska, D. A. et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J. Infect. Dis. 211, 1800–1812 (2015).

41.          Levine, H., Kopel, E., Anis, E., Givon-Lavi, N. & Dagan, R. The impact of a national routine immunisation programme initiated in 1999 on Hepatitis A incidence in Israel, 1993 to 2012. Eurosurveillance 20, (2015).

42.          Kopel, E. et al. Long-term predictors of recurrent laboratory-confirmed giardiasis: A 10-year national surveillance study. J. Pediatric Infect. Dis. Soc. 3, 343–346 (2014).

43.          Shulman, L. M. et al. Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013. J. Infect. Dis. 210, S304–S314 (2014).

44.          Elinav, H. et al. Pregnancy-associated listeriosis: Clinical characteristics and geospatial analysis of a 10-year period in Israel. Clin. Infect. Dis. 59, 953–961 (2014).

45.          Gandacu, D. et al. Resurgence of cutaneous leishmaniasis in Israel, 2001-2012. Emerg. Infect. Dis. 20, 1605–1611 (2014).

46.          Anis, E. et al. West Nile fever in Israel: The reemergence of an endemic disease. J. Infect. 68, 170–175 (2014).

47.          Moran-Gilad, J. et al. Molecular epidemiology of Legionnaires’ disease in Israel. Clin. Microbiol. Infect. 20, 690–696 (2014).

48.          Anis, E. et al. Rubella in Israel after the MMR vaccine: Elimination or containment? J. Public Health Policy 34, 288–301 (2013).

49.          Avidor, B. et al. Transmission Patterns of HIV-Subtypes A/AE versus B: Inferring Risk-Behavior Trends and Treatment-Efficacy Limitations from Viral Genotypic Data Obtained Prior to and during Antiretroviral Therapy. PLoS One 8, (2013).

50.          Ginsberg, G. M. et al. Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis. Isr. J. Health Policy Res. 2, (2013).

51.          Anis, E. et al. Insidious reintroduction of wild poliovirus into israel, 2013. Eurosurveillance 18, (2013).

52.          Levy, Y., Anis, E., Kaliner, E., Grotto, I. & Danon, Y. L. Estimated size of the population at risk of severe adverse events after smallpox vaccination in Israel. Vaccine 30, 6632–6635 (2012).

53.          Moran-Gilad, J. et al. Huhumidifier-associated paediatric legionnaires’ disease, Israel, February 2012. Eurosurveillance 17, (2012).

54.          Anis, E. et al. Mumps outbreak in Israel’s highly vaccinated society: Are two doses enough? Epidemiol. Infect. 140, 439–446 (2012).

55.          Engelhard, D. et al. Increased extent of and risk factors for pandemic (H1N1) 2009 and seasonal infl uenza among children, Israel. Emerg. Infect. Dis. 17, 1740–1743 (2011).

56.          Anis, E. et al. Recent trends in human brucellosis in Israel. Isr. Med. Assoc. J. 13, 359–362 (2011).

57.          Levy, I. et al. Men who have sex with men, risk behavior, and HIV infection: Integrative analysis of clinical, epidemiological, and laboratory databases. Clin. Infect. Dis. 52, 1363–1370 (2011).

58.          Muhsen, K. et al. Sero-prevalence of mumps antibodies in subpopulations subsequently affected: By a large scale mumps epidemic in Israel. Vaccine 29, 3878–3882 (2011).

59.          Anis, E. et al. A cluster of deaths following influenza vaccination, Israel, 2006. J. Public Health Policy 31, 318–323 (2010).

60.          Anis, E. et al. Measles in a highly vaccinated society: The 2007-08 outbreak in Israel. J. Infect. 59, 252–258 (2009).

61.          Anis, E. et al. Smallpox revaccination of 21 000 first responders in Israel: lessons learned. Int. J. Infect. Dis. 13, 403–409 (2009).

62.          Balicer, R. D. et al. Influenza A/H1N1 in Israel--clinical and epidemiological characteristics. Harefuah 148, 738-742,795 (2009).

63.          Pezzoli, L. et al. Packed with Salmonella - Investigation of an international outbreak of Salmonella Senftenberg infection linked to contamination of prepacked Basil in 2007. Foodborne Pathog. Dis. 5, 661–668 (2008).

64.          Elinav, E. et al. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J. Hepatol. 47, 514–520 (2007).

65.          Moerman, L. et al. The re-emergence of pertussis in Israel. Isr. Med. Assoc. J. 8, 308–311 (2006).

66.          Dagan, R. et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294, 202–210 (2005).

67.          Ben-Ami, R. et al. Malaria in travelers returning from short organized tours to holiday resorts in Mombassa, Kenya. Isr. Med. Assoc. J. 7, 364–367 (2005).

68.          Sidi, G. et al. Tickborne relapsing fever in Israel. Emerg. Infect. Dis. 11, 1784–1786 (2005).

69.          Anis, E., Pener, H., Goldmann, D. & Leventhal, A. The reemergence of malaria in Israel? Harefuah 143, 815–819 (2004).

70.          Ben-Simon, G. J. et al. Spectacle use and reduced unaided vision in third grade students: A comparative study in different educational settings. Clin. Exp. Optom. 87, 175–179 (2004).

71.          Green, M. S., Anis, E., Gandacu, D. & Grotto, I. The fall and rise of gonorrhoea incidence in Israel: An international phenomenon? Sex. Transm. Infect. 79, 116–118 (2003).

72.          Slater, P. E., Anis, E. & Leventhal, A. Communicable Disease Control: An introductory course for MPH students. Public Health Rev. 30, 327–338 (2002).

73.          Slater, P. E., Anis, E. & Leventhal, A. Preparation for an outbreak of smallpox in Israel. Isr. Med. Assoc. J. 4, 507–512 (2002).

74.          Green, M. S. et al. The changing epidemiology of viral hepatitis A in Israel. Isr. Med. Assoc. J. 3, 347–351 (2001).

75.          Slater, P. E., Leventhal, A. & Anis, E. The elimination of smallpox from Israel. Isr. Med. Assoc. J. 3, 71–72 (2001).

76.          Anis, E., Leventhal, A., Elkana, Y., Wilamowski, A. & Pener, H. Cutaneous leishmaniasis in Israel in the era of changing environment. Public Health Rev. 29, 37–47 (2001).

77.          Anis, E., Leventhal, A., Roitman, M. & Slater, P. E. Introduction of routine hepatitis A immunization in Israel--the first in the world. Harefuah 138, 177-180,272 (2000).

78.          Aharonowitz, G., Koton, S., Segal, S., Anis, E. & Green, M. S. Epidemiological characteristics of spotted fever in Israel over 26 years. Clin. Infect. Dis. 29, 1321–1322 (1999).

79.          Slater, P. E., Anis, E. & Leventhal, A. Measles control in Israel: A decade of the two-dose policy. Public Health Rev. 27, 235–241 (1999).

80.          Slater, P. E., Anis, E. & Leventhal, A. The control of mumps in Israel. Eur. J. Epidemiol. 15, 765–767 (1999).

81.          Dagan, R. et al. Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. Vaccine 17, 134–141 (1999).

82.          Ostroi, P., Anis, E. & Green, M. S. Shigellosis in Israel - Update 1995. Public Health Rev. 24, 213–225 (1996).

83.          Slater, P. E., Roitman, M., Leventhal, A. & Anis, E. Control of rubella in Israel: Progress and challenge. Public Health Rev. 24, 183–192 (1996).

84.          Modan, B. et al. The need for liver transplantation: a nationwide estimate based on consensus review. Lancet 346, 660–662 (1995).

85.          Slater, P. E., Roitman, M. & Anis, E. Failure of mass chemoprophylaxis to control hyperendemic meningococcal disease. Public Health Rev. 23, 367–369 (1995).